Trademark: 90808336
Word
OPMIZTA
Status Date
Thursday, June 6, 2024
Filing Date
Friday, July 2, 2021
Published for Opposition
Tuesday, April 26, 2022
5 Pharmaceutical preparation, namely, a recombinant, human monoclonal antibody antigen-binding fragment designed to reverse the antiplatelet activity of ticagrelor in major bleeding and urgent surgery situations
Jul 6, 2021
New Application Entered
Sep 13, 2021
New Application Office Supplied Data Entered
Mar 23, 2022
Assigned To Examiner
Mar 23, 2022
Approved For Pub - Principal Register
Apr 6, 2022
Notification Of Notice Of Publication E-Mailed
Apr 26, 2022
Published For Opposition
Apr 26, 2022
Official Gazette Publication Confirmation E-Mailed
Jun 21, 2022
Noa E-Mailed - Sou Required From Applicant
Dec 12, 2022
Sou Teas Extension Received
Dec 12, 2022
Sou Extension 1 Filed
Dec 12, 2022
Sou Extension 1 Granted
Dec 14, 2022
Notice Of Approval Of Extension Request E-Mailed
Feb 8, 2023
Automatic Update Of Assignment Of Ownership
Apr 18, 2023
Teas Withdrawal Of Attorney Received
Apr 18, 2023
Withdrawal Of Attorney Granted
Jun 21, 2023
Sou Teas Extension Received
Jun 21, 2023
Sou Extension 2 Filed
Jun 21, 2023
Sou Extension 2 Granted
Jun 23, 2023
Notice Of Approval Of Extension Request E-Mailed
Dec 21, 2023
Sou Teas Extension Received
Dec 21, 2023
Sou Extension 3 Filed
Jan 2, 2024
Attorney/Dom.Rep.Revoked And/Or Appointed
Jan 2, 2024
Teas Change Of Correspondence Received
Jan 2, 2024
Teas Revoke/App/Change Addr Of Atty/Dom Rep Received
Jan 10, 2024
Automatic Update Of Assignment Of Ownership
Jan 12, 2024
Case Assigned To Intent To Use Paralegal
Jan 12, 2024
Sou Extension 3 Granted
Jan 13, 2024
Notice Of Approval Of Extension Request E-Mailed
Jun 6, 2024
Sou Teas Extension Received
Jun 6, 2024
Sou Extension 4 Granted
Jun 6, 2024
Sou Extension 4 Filed
Jun 13, 2024
Notice Of Approval Of Extension Request E-Mailed
Trademark Alertz updated from USPTO on 2030-01-24
